Clinical trial
A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-β-1a 44 mcg Tiw SC (Rebif®) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.
NCT00391352 is registered in ClinicalTrials.gov with Waukesha Memorial Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-β-1a 44 mcg Tiw SC (Rebif®) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.
- Lead sponsor
- Waukesha Memorial Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 29, 2008
- Completion date
- August 31, 2012
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsing-remitting multiple sclerosis